Gelion Burns Its Own Revenue Line to Buy a Single Black Powder

A new CEO winds down the BESS integration unit, parks recycling in strategic review, and bets FY2027 on one sulfur cathode — while two consecutive CEOs field the same share-price question

GELN.L · Earnings Call · 2026-10-22

The axe, not the cheque

Most loss-making deep-tech calls ask investors for patience. This one asked them to surrender revenue. New chief executive Matt Wood — three or four months into the seat after John Wood's retirement — used the FY2026 print to close the integration solutions business, the battery energy storage installation unit that had booked roughly £900,000 in FY2025 and, by the CFO's own account, "almost nil this year."

So we have taken the difficult decision to wind down our integration solutions product offering... after delivering successfully an initial project, the market has become significantly more challenging. It's become commoditized and oversupplied, and Gelion doesn't have a sustainable competitive advantage in that market.
Matthew Wood, Chief Executive Officer · 2026-10-22

That is a reversal worth marking. Nine months ago the same division was being praised in the Q&A as a contributor to group earnings — “Amit did talk to you about all the things that we're doing and have been doing around cost management and around earning revenue, our hard-working integration services division, in particular.” — John Wood, CEO · 2025-11-28 The recycling unit gets the softer treatment: not closed, but shoved into strategic review, with the explicit hint that a partner may be a "better path forward." In March the previous CEO had sketched a revenue path for it — “The recycling business is currently moving from lab scale with a goal to go up to pilot scale. As they go from pilot scale... then they would be getting revenue.” — John Wood, Unknown · 2026-03-02 That promise is now off the table as a standalone story. The stated saving is around £800,000 a year, recycled straight back into the NES cathode programme without widening the operating envelope. Strategically tidy. Rhetorically, though, it is a company admitting that two of its three business units were diluting the third.

What the £800,000 buys

Underneath the pruning sits a genuinely impressive run of partner validation. TDK has cycled the material in multilayer pouch cells in Japan at 1C, 100% depth of discharge, holding a near-flat capacity line past 300 cycles. QinetiQ's ARMD4 programme ran 6C vertical take-off, 3C cruise and 6C landing pulses, fifty times over, in a defence drone profile. The National Lab of the Rockies retained 92% of capacity across a 20-fold rate increase — and, critically, offers a route into US government procurement. The CTO was unusually candid about why the TDK data matters more than the lab numbers: “there's a variety of ways that you can cheat when you make a battery... those are some of the laser results that we have where we've removed those, let's say, artificial advantages.” — Louis Adriaenssens, Chief Technical Officer · 2026-10-22 That is the kind of claim that survives diligence. The stable now includes Nissan Europe on solid-state, a top-15 and a top-5 automotive OEM, plus the funded Mitsui Kinzoku JDA worth roughly £2 million, whose first payment was invoiced and, per the CFO, already received in cash in October. The defence angle is where Gelion brushes against a live market theme rather than just a sector one. The CTO pointed at the Department of War as the institutional pathway behind the Rockies work — the same Department of Defense procurement thread that RTX and CRS leaned on in their own calls this week. Battery chemistry for things that fly is a real budget line, not a slide.

The timeline problem

Here is where the story gets its teeth. The CEO's framing on orders was almost aggressively confident: “there is nothing stopping us in getting to commercial orders other than time.” — Matthew Wood, Chief Executive Officer · 2026-10-22 Then the CFO supplied the number — “We start generating commercial revenues, although modest at this stage, but we will generate commercial revenues in FY 2027.” — Amit Gupta, Chief Financial Officer · 2026-10-22 The gap between those two sentences is the entire investment case. "Nothing but time" is a technology claim; "modest" FY2027 commercial revenue is a cash-flow claim, and only one of them pays the bills. Which is why the balance sheet carried the day. Adjusted EBITDA loss of £4.1 million beat a £4.4 million consensus; pro forma cash of £9.6 million at 30 June came in roughly a fifth above expectations; grant-funded R&D jumped to 63.2% of the development programme from 49.8%. That is a genuinely good year of stewardship, and it is the fifth consecutive year management has cleared consensus. The £5 million annual spend envelope is being held. But the share price question arrived first in the Q&A, and it arrived phrased exactly as it was nine months ago. Wood's answer — “we are acutely aware of the share price, but I don't dwell on the share price. We don't control it directly” — Matthew Wood, Chief Executive Officer · 2026-10-22 — is the same shrug his predecessor offered: “The share market is the share market. I concentrate on the performance of the company.” — John Wood, CEO · 2025-11-28 Two CEOs, two languages, identical deflection. When a cap raise question and a share-price question both make the quarter's keyword set, the market is voting whether or not management wishes to acknowledge it. The CFO's rebuttal — a clear going-concern opinion from the auditors — answers solvency, not sentiment.

The sodium question, reframed

The most instructive exchange was the one about sodium-ion, which topped Gelion's own keyword list this quarter as sodium ion advances accelerated across the industry. The answer was a textbook pivot from threat to optionality: “I actually don't see sodium ion as a threat. I see it as an opportunity.” — Matthew Wood, Chief Executive Officer · 2026-10-22 The CTO then closed the loop — sodium cannot serve the lightweight, high-power aerospace and drone markets Gelion is targeting first. So the technology that could theoretically commoditise the cathode space is cast as a future revenue stream rather than a competitive risk. It is a fair argument. It is also the argument a company makes when a substitute appears. What changed is focus, not physics. The cathode market deficit thesis is unchanged, the market validation is broader and more credible than a year ago, and the domestic supply chain pitch — sulfur as an oil-refining by-product — has only strengthened geopolitically. What changed is that Gelion now has one product, one strategy, and a public promise of modest revenue next year. The pruning is right. The saving is small. The next twelve months will be judged on a single question: does the commercial orders pipeline convert before the £9.6 million does. Everything else on this call was prelude.